47.71
0.44%
0.21
Handel nachbörslich:
47.71
Schlusskurs vom Vortag:
$47.50
Offen:
$46.92
24-Stunden-Volumen:
2.41M
Relative Volume:
1.16
Marktkapitalisierung:
$119.62B
Einnahmen:
$53.04B
Nettoeinkommen (Verlust:
$4.93B
KGV:
15.03
EPS:
3.1735
Netto-Cashflow:
$9.91B
1W Leistung:
+1.94%
1M Leistung:
-0.15%
6M Leistung:
+1.84%
1J Leistung:
-1.04%
Sanofi Adr Stock (SNY) Company Profile
Vergleichen Sie SNY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
47.71 | 119.62B | 53.04B | 4.93B | 9.91B | 1.9736 |
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-07-26 | Bestätigt | Argus | Buy |
2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
2024-01-16 | Fortgesetzt | UBS | Buy |
2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-10-30 | Herabstufung | Stifel | Buy → Hold |
2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
2022-08-09 | Herabstufung | UBS | Buy → Neutral |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | Eingeleitet | Bernstein | Outperform |
2019-08-14 | Hochstufung | UBS | Neutral → Buy |
2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
2018-10-09 | Eingeleitet | Guggenheim | Neutral |
2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
2018-03-23 | Hochstufung | Liberum | Hold → Buy |
2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Communiqué de presse - GlobeNewswire Inc.
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug - Investor's Business Daily
What Did We Find About Insider Trading At Sanofi ADR (NASDAQ: SNY)? - Stocks Register
Weekly Upgrades and Downgrades - InvestorPlace
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN
Top-3 International Stocks Beating Their U.S. Peers for Dividend Earnings - TheStreet
Novo Nordisk and AstraZeneca top 2025 drug picks for US investment bankread why - Proactive Investors USA
Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest in? - Insider Monkey
12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
How Robert F. Kennedy Jr. Will Bring Major Uncertainties to U.S. Healthcare - Barron's
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Here’s Why Mastercard Incorporated (NYSE: MA) Is An Attractive Investment Right Now - Stocks Register
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo Finance
16 New 4-Star Stocks - Morningstar
Biggest stock movers Monday: DJT, crypto stocks, and more - MSN
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):